Ting YS, et al. - Whether the inclusion of CD200 holds value in the assessment of atypical chronic lymphocytic leukemia (CLL) cases by flow cytometry was investigated in this study including 70 control samples, 63 samples with CLL or atypical CLL phenotype, 6 mantle cell lymphoma (MCL) samples, and 40 samples of other mature B cell neoplasms. Using eight-color flow cytometry in combination with a conventional panel of flow cytometry markers, researchers studied CD200 expression on mature B cell neoplasms. They found that CD200 demonstrated utility as a marker for differentiating between CLL and MCL by flow cytometry. Specifically, its utility was evident in discriminating CLL samples with atypical immunophenotypes from MCL.